Matches 1 - 20 out of 20


Match Document Document Title
DE102007063902B3 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being an aptamer that binds to activated protein C, the aptamer having a dissociation constant KD binds to activated...
DE102007041476B4 Aptamers that bind to a target molecule involved in hemostasis  
Aptamer that binds to a target molecule involved in hemostasis, the aptamer being a thrombin-binding fusion aptamer, comprising at least two thrombin-binding aptamers and at least one linker, the...
DE102004038535B4 Cellular introduction of nucleic acid agents  
Use of a phosphorothioate-modified nucleic acid to improve the effect of a medicament containing siRNA.
DE102009050308A1 New polyribonucleotide, having protein encoding sequence that comprises combination of unmodified and modified nucleotides and is obtained from mixture of ATP, guanosine-, cytidine- and uridine-triphosphate, useful e.g. for coating implant  
Polyribonucleotide (I), having a sequence encoding a protein or its fragments, is new, where (I) comprises a combination of unmodified and modified nucleotides and is obtained from a nucleotide...
DE102007041476A1 Aptamers that bind to a party to the hemostasis target molecule  
The Invention relates to an aptamer that binds to an haemostasis participating target molecule binds with the aptamer an aptamer is that binds to activated protein C, wherein the aptamer with a...
DE102004054730A1 Serum stable amphoteric liposomes  
The Invention relates to amphoteric liposomal formulations, the special show serum stability and the intracellular Delivery of oligonucleotides suitable.
DE102004038535A1 Cellular infiltration of nucleic acid agents  
The Invention is the use of at least a first, Phosphorothioate-modified nucleic acid to improve the cellular uptake at least a second nucleic acid. It further relates to a pharmaceutical...
DE102004016020A1 Amphoteric liposomal formulations, especially for parenteral applications, contains at least one active substance and neutral lipids as the liposomes with serum stability  
Amphoteric liposomal formulations, with serum stability and with at least one active substance in a watery solution, having liposomes as neutral lipids with a membrane content of 10-60 mol.% and...
DE102004002351A1 New RNA aptamers specific for lipopolysaccharide-binding protein, useful for diagnosis and treatment of sepsis, inhibit the lipopolysaccharide-induced signaling cascade  
RNA aptamers (I), or their alleles and/or derivatives, that bind specifically to lipopolysaccharide-binding protein (LBP) are new. An independent claim is also included for a method for preparing...
DE10361502A1 Cosmetic or pharmaceutical preparations containing super structure-forming nucleic acid sequences  
The This invention relates to cosmetic or pharmaceutical Preparations for the prophylaxis and / or treatment of epithelial integument, contain the super structure-forming nucleic acid sequences...
DE10322662A1 New DNA type 10-23 enzyme, useful for treating e.g. pain, and related short interfering RNA, directed against the vanillin receptor or picorna viruses, contains specific nucleotide modifications for improved stability  
DNA enzyme (A) of type 10-23 comprising in the 5' to 3' direction: first substrate recognition arm (I); catalytic core sequence (II) and second substrate recognition arm (III). The new feature is...
DE10258677A1 Combined use of antisense oligonucleotides for treating cancer, directed against the Polo-like kinase 1 and B cell leukemia/lymphoma 2 genes, having a synergistic effect  
Combined use of an antisense oligodeoxynucleotide (ON1) against polo-like kinase 1 (Plk1) and an oligodeoxynucleotide (ON2) against the B cell leukemia/lymphoma 2 proto-oncogene (Bcl2) to prepare...
DE10309368A1 Pharmaceutical formulation having RNA as a cofactor of haemostasis  
It pharmaceutical preparations are described which contain the promotion of blood coagulation as well as for the promotion of fibrinolysis sufficient quantities of RNA or one or more...
DE10229872A1 Immunostimulation by chemically modified RNA  
The present invention relates to a immu nstimulierendes agent containing at least one chemically modified RNA. The invention further relates to a vaccine containing at least an antigen in...
DE10209564A1 Antitumoral and antineoplastic medicaments, effective against carcinoma, sarcoma, lymphoma and leukemia, comprise new or known nucleoside-sulfur containing phospholipid derivatives  
Nucleoside-sulfur containing phospholipid derivatives (I), which on adminstration to humans directly or indirectly provide (I) or other antitumoral or antiproliferative active metabolites or their...
DE10160151A1 Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang  
Inhibiting expression of a target gene (I) in a cell by introducing an inhibitory RNA (dsRNA1) having a double-stranded structure of at most 49 consecutive bases, is new. At least part of one...
DE10100586C1 Inhibiting gene expression in cells, useful for e.g. treating tumors, by introducing double-stranded complementary oligoRNA having unpaired terminal bases  
Method for inhibiting expression of a target gene (A) in a cell by introducing at least one oligoribonucleotide (O1) that has a double-stranded (ds) structure consisting of at most 49 sequential...
DE10020275A1 New 2-deoxy-L-ribose and 2-deoxy-D-ribose precursors useful as intermediates for therapeutic nucleic acids and oligonucleotides  
(4R,5S)-4-silyl-5-hydroxymethyl-tetrahydro-2-furanone derivatives (I), (4S,5R)-4-silyl-5-hydroxymethyl-tetrahydro-2-furanone derivatives (I'),...
DE19935303A1 Oligonucleotides for inhibiting the expression of human Eg5  
The invention relates to an oligonucleotide or one of its derivatives that is characterized by a sequence that corresponds to a nucleotide sequence that encodes a defined part of human eg5 or a...
DE19900743A1 New complexing proteins  
The invention relates to a complex comprised of unnaturally occurring, specifically complex-forming proteins containing the following components: a) at least one ligand which is specific for a...

Matches 1 - 20 out of 20